Published in Medical Verdicts and Law Weekly, September 20th, 2007
This trend article about University of Mainz, Germany, is an immediate alert from NewsRx to identify developing directions of research.
Study 1: Investigators publish new data in the report "Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain." According to recent research published in the British Journal of Clinical Pharmacology, "The purpose of the current study was to establish the safety and maximal tolerated dose of CNS 5161 HCl. Forty patients with chronic neuropathic pain (23 male, 17 female)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.